Table 1.
Patients’ characteristics and the comparison for characteristics and outcomes in PTCY and non-PTCY groups
| Total (n = 52) |
Group | p value | |||
|---|---|---|---|---|---|
| PTCY (n = 31) | non-PTCY (n = 21) | ||||
| Age, years | 5.8 (1.1,13.5) | 6.04 (SD = 3.13) | 6.15 (SD = 3.47) | 0.913 | |
| Sex, n | male | 37 | 23 | 14 | 0.557 |
| female | 15 | 8 | 7 | ||
| Weight, kg | 17.6 (9.0, 42.4) | 19.35 (SD = 7.47) | 18.60 (SD = 6.35) | 0.707 | |
| Primary diagnosis, n | AML | 27 | 19 | 8 | 0.259 |
| ALL | 23 | 11 | 12 | ||
| others | 2 | 1 | 1 | ||
| Remission status, n | CR1 | 47 | 27 | 20 | 0.329 |
| CR2 | 5 | 4 | 1 | ||
| HLA matching, n | 7/10 | 4 | 3 | 1 | 0.704 |
| 8/10 | 22 | 14 | 8 | ||
| 9/10 | 17 | 10 | 7 | ||
| 10/10 | 9 | 4 | 5 | ||
| HLA matching 2, n | 7/10 or 8/10 | 26 | 17 | 9 | 0.329 |
| 9/10 or 10/10 | 26 | 14 | 12 | ||
| TNC, 107/kg (range) | 6.15 (3.3, 15.3) | 6.78 (5.5, 8.06) | 6.31 (3.29, 11.15) | 0.801 | |
| CD34+, 105/kg (range) | 2.61 (0.72, 11.6) | 3.25 (1.26, 10.7) | 1.97 (0.72, 11.6) | 0.003 | |
| Follow-up, months (range) | 21.6 (1.8, 38.2) | 14.4 (1.8, 30.0) | 34.3 (2.2, 38.1) | < 0.001 | |
| Neutrophil engraftment, days (range) | 14 (11, 22) | 15.8 (14.6, 16.9) | 14.5 (11,19) | 0.160 | |
| PLT engraftment, days (range) | 32 (12, 61) | 31.9 (27.8, 35.9) | 34.5 (13, 52) | 0.233 | |
| Graft failure, n (%) | 2 (4) | 1 (3) | 1 (5) | 0.777 | |
| PES, n (%) | 45 (87) | 25 (81) | 20 (95) | 0.130 | |
| Corticosteroid responding PES, n (%) | 38 (73) | 17 (71) | 19 (95) | 0.054 | |
| Acute GvHD, n (%) | 42 (81) | 24 (77) | 18 (86) | 0.456 | |
| Grade 3 and 4 Acute GvHD, n (%) | 20 (38) | 13 (42) | 7 (33) | 0.532 | |
| HC, n (%) | 14 (27) | 7 (23) | 7 (33) | 0.431 | |
| Chronic GvHD, n (%) | 24 (46) | 13 (42) | 11 (52) | 0.458 | |
| EBV activity, n (%) | 1(2) | 0 (0) | 1 (5) | 0.404 | |
| CMV activity, n (%) | 6 (12) | 5 (16) | 1 (5) | 0.211 | |
| pneumonia, n (%) | 17 (33) | 10 (32) | 7 (33) | 0.584 | |
| Fungal infection, n (%) | 8 (15) | 7 (23) | 1 (5) | 0.081 | |
| Sepsis or bacteremia, n (%) | 11 (21) | 10 (32) | 1 (5) | 0.017 | |
| TRM, n (%) | 4 (8) | 3 (10) | 1 (5) | 0.514 | |
| Relapse, n (%) | 7 (13) | 6 (19) | 1 (5) | 0.130 | |
| Event-free survival, n (%) | 41 (79) | 22 (71) | 19 (91) | 0.091 | |
PTCY posttransplant cyclophosphamide, SD standard deviation, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia; others, mixed lineage leukemia, CR1 first complete remission, CR2 second complete remission, HLA human lymphocyte antigen, TNC total nucleated cell, CD34+ CD 34+ cell counts, PLT Platelet, GvHD Graft-versus-host-disease, HC Hemorrhagic cystitis, EBV Epstein-Barr virus, CMV Cytomegalovirus, PES peri-engraftment syndrome, TRM Transplantation related mortality